Endo Pharmaceuticals Reports Q4 EPS of $1.06 vs. $0.96

Endo Pharmaceuticals ENDP today reported financial results for the fourth quarter 2010. Total revenues during the fourth quarter of 2010 increased 31 percent to $511 million, compared with $391 million in the same quarter of 2009. Net income for the three months ended December 31, 2010 was $93 million, compared with $14 8 million in the comparable 2009 period. Adjusted net income for the three months ended December 31, 2010, was $128 million, compared with $95 million in the same period in 2009. Reported diluted earnings per share for the quarter ended December 31, 2010 were $0.77 compared with $1.25 in the fourth quarter of 2009. Adjusted diluted earnings per share for the same period were $1.06 compared with $0.81 reported in 2009.